Skin Diseases, Papulosquamous: Clinical Trials

1410 completed, 246 unknown, 197 recruiting, 126 terminated. 429 Phase 2, 371 Phase 3, 354 Not applicable, 252 Phase 4, 230 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	429	Completed 310, Terminated 38, Unknown 25, Recruiting 21, Not yet recruiting 12, Withdrawn 10, Active not recruiting 9, Suspended 3, Enrolling by invitation 1
Phase 3	371	Completed 280, Active not recruiting 22, Terminated 20, Recruiting 16, Unknown 16, Not yet recruiting 9, Withdrawn 6, Enrolling by invitation 2
Not applicable	354	Completed 185, Unknown 62, Recruiting 44, Not yet recruiting 24, Terminated 14, Active not recruiting 13, Withdrawn 9, Enrolling by invitation 2, Suspended 1
Phase 4	252	Completed 159, Unknown 35, Recruiting 22, Terminated 12, Not yet recruiting 8, Withdrawn 8, Active not recruiting 7, Enrolling by invitation 1
Phase 1	230	Completed 167, Terminated 20, Unknown 17, Recruiting 15, Active not recruiting 5, Not yet recruiting 3, Withdrawn 2, Enrolling by invitation 1
Early Phase 1	27	Unknown 9, Completed 8, Recruiting 3, Terminated 3, Withdrawn 3, Enrolling by invitation 1

Follow Skin Diseases, Papulosquamous: new trials by email Literature Review of Skin Diseases, Papulosquamous trials Research Report on Skin Diseases, Papulosquamous

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis	Phase 2	Not yet recruiting	National Institute of Unani Medicine, Bengaluru	54	2027-04-01	2026-09-25
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) DDY391 - Moderate to Severe Psoriatic Arthritis	Phase 2	Not yet recruiting	Novartis Pharmaceuticals	88	2027-02-10	2026-11-06
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis	Phase 3	Not yet recruiting	Takeda	644	2027-01-11	2026-10-27
Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis Patient-Reported Outcomes Dashboard With Goal Setting - Arthritis, Psoriatic (PsA), Arthritis, Rheumatoid (RA)	Not applicable	Not yet recruiting	Northwestern University	160	2027-01-01	2026-10-15
Assessing Psoriasis Treatment Outcomes Artificial intelligence, Human, Standard of Care - Psoriasis	Not applicable	Not yet recruiting	Wake Forest University Health Sciences	15	2027-01-01	2026-11-05
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease	Phase 3	Not yet recruiting	Bristol-Myers Squibb	2300	2026-12-31	2026-09-03
Apremilast and Adalimumab in Psoriatic Arthritis Patients Adalimumab, Apremilast - Psoriatic Arthritis, Ultrasound Assessment	Not applicable	Not yet recruiting	Tanta University	60	2026-12-30	2026-09-08
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA)	Phase 2	Not yet recruiting	Forward Therapeutics	210	2026-12-01	2026-10-09
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation Apremilast XR, Apremilast IR - Psoriasis, Arthritis, Psoriatic	Phase 1	Not yet recruiting	Amgen	114	2026-11-18	2026-11-02
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis Zasocitinib - Palmoplantar Psoriasis	Phase 3	Not yet recruiting	Takeda	40	2026-11-16	2026-11-04
Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis Investigational cream - Atopic Dermatitis, Psoriasis	Not applicable	Not yet recruiting	Brainfarma Industria Química e Farmacêutica S/A	42	2026-11-06	2026-11-05
Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis Pentoxifylline 400 mg Oral Tablet, Placebo - Psoriasis	Not applicable	Not yet recruiting	Wasuchon Chaichan	140	2026-11-01	2026-10-06
An AI-Based Erythema Measurement System for Psoriasis Lesions No additional drugs(control Group) - Psoriasis		Not yet recruiting	Khon Kaen University	50	2026-11-01	2026-08-05
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis COL-5671-PRO, Placebo - Plaque Psoriasis	Phase 2	Not yet recruiting	Coultreon Biopharma	100	2026-10-31	2026-11-03
Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. Crisaborole 2% topical ointment, tacrolimus ointment 0.1% - Psoriasis, Psoriasis Genital	Phase 3	Not yet recruiting	Cairo University	40	2026-10-25	2026-10-27
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) MK-8644, Placebo for MK-8644 - Psoriasis, Healthy	Phase 1	Recruiting	Merck Sharp & Dohme LLC	132	2026-10-20	2026-10-27
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis	Phase 2	Recruiting	Novartis Pharmaceuticals	220	2026-10-14	2026-10-13
A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults HCXT-2001 Tablets, Placebo, HCXT-2001 Tablets(A) - Psoriasis	Phase 1	Not yet recruiting	Shanghai Peptidstar Therapeutics Limited	40	2026-10-14	2026-10-13
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis Raster-Scan Optoacoustic Mesoscopy, Multispectral Optoacoustic Tomography, Skin Biopsy and Skin Sample Collection - Psoriasis (PsO), Psoriasis Arthritis	Not applicable	Not yet recruiting	University of Erlangen-Nürnberg Medical School	192	2026-10-07	2026-10-21
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA) Narrowband UVB Phototherapy, Ceramol PSOR Cream, Comparator Emollient Cream - Psoriasis, Psoriasis; Plaque	Not applicable	Not yet recruiting	Unifarco SpA	128	2026-10-01	2026-09-30

Showing 20 of 2223. Sign in to see all of them.

Narrower conditions

Psoriasis (1469)  ·  Arthritis, Psoriatic (594)  ·  Arthritis, Rheumatoid (204)  ·  Lichen Planus, Oral (137)  ·  Spondylitis, Ankylosing (112)  ·  Dermatitis, Atopic (80)  ·  Lichen Planus (66)  ·  Skin Diseases (66)  ·  Arthritis (64)  ·  Crohn Disease (61)  ·  Dermatitis, Seborrheic (56)  ·  Colitis, Ulcerative (46)  ·  Spondylarthritis (40)  ·  Inflammation (36)  ·  Pruritus (36)

Broader conditions

Skin and Connective Tissue Diseases (2220)  ·  Skin Diseases (2157)  ·  Musculoskeletal Diseases (639)  ·  Joint Diseases (625)  ·  Bone Diseases (611)  ·  Spinal Diseases (607)  ·  Spondylitis (600)  ·  Spondylarthropathies (587)  ·  Arthritis (569)  ·  Spondylarthritis (567)  ·  Psoriasis (468)  ·  Immune System Diseases (349)  ·  Pathological Conditions, Signs and Symptoms (232)  ·  Connective Tissue Diseases (225)

Interventions

secukinumab (95)  ·  Adalimumab (93)  ·  Etanercept (87)  ·  Methotrexate (65)  ·  apremilast (63)  ·  Ustekinumab (59)  ·  guselkumab (50)  ·  risankizumab (43)  ·  Infliximab (41)  ·  deucravacitinib (35)  ·  bimekizumab (32)  ·  tofacitinib (29)  ·  Clobetasol (28)  ·  ixekizumab (28)  ·  calcipotriene (27)

Sponsors

Novartis Pharmaceuticals (72)  ·  AbbVie (65)  ·  Amgen (63)  ·  Pfizer (53)  ·  Cairo University (40)  ·  Bristol-Myers Squibb (39)  ·  Janssen Research & Development, LLC (34)  ·  Eli Lilly and Company (30)  ·  AbbVie (prior sponsor, Abbott) (23)  ·  UCB Biopharma SRL (23)  ·  Bausch Health Americas, Inc. (21)  ·  Boehringer Ingelheim (21)  ·  Merck Sharp & Dohme LLC (21)  ·  Abbott (20)  ·  Assistance Publique - Hôpitaux de Paris (16)

Countries

United States (776)  ·  Germany (305)  ·  Canada (288)  ·  France (211)  ·  Poland (197)  ·  United Kingdom (194)  ·  Spain (182)  ·  China (170)  ·  Italy (144)  ·  Hungary (126)  ·  Belgium (119)  ·  Australia (117)  ·  Czechia (115)  ·  Japan (101)  ·  Russia (99)

Top investigators

Robert Bissonnette, MD (12)

Results publications

PMID 37316690, PMID 37906417, PMID 32816215, PMID 35544084, PMID 30739254, PMID 31667790, PMID 38446397, PMID 31054118, PMID 32207067, PMID 35305260, PMID 37400681, PMID 38488975, PMID 39120849, PMID 39578348, PMID 40194794, PMID 41060492, PMID 41580158, PMID 41800601, PMID 41807031, PMID 42825996, PMID 25913550, PMID 27573260, PMID 27576559, PMID 34110605, PMID 34795065, PMID 34921669, PMID 35279805, PMID 35393269, PMID 36178584, PMID 36642439, PMID 36751950, PMID 37076998, PMID 37341961, PMID 37950894, PMID 39073712, PMID 39120848, PMID 40241921, PMID 40286813, PMID 40886218, PMID 41359217, PMID 26547918, PMID 26953848, PMID 27299809, PMID 29380251, PMID 30018799, PMID 31077258, PMID 31112005, PMID 31203228, PMID 31909868, PMID 31964419

NIH funding

2016 (36), 2018 (26), 2023 (26), 2017 (23), 2014 (20), 2015 (16), 2019 (16), 2025 (10), 2005 (7), 2009 (7), 2008 (2), K08CA237619 (1), K23AR080043 (1), K23HL152013 (1), P20GM130414 (1)